%0 Journal Article
%T CDK12 inactivation across solid tumors: an actionable genetic subtype
%A Catherine H. Marshall
%A Eddie L. Imada
%A Emmanuel S. Antonarakis
%A Luigi Marchionni
%A Zhuojun Tang
%J Archive of "Oncoscience".
%D 2019
%R 10.18632/oncoscience.481
%X Inactivating CDK12 alterations have been reported in ovarian and prostate cancers and may have therapeutic implications; however, the prevalence of these mutations across other cancer types is unknown. We searched the cBioPortal and GENIE Project (public release v4.1) databases for cancer types with > 200 sequenced cases, that included patients with metastatic disease, and in which the occurrence of at least monoallelic CDK12 alterations was > 1%. The prevalence of at least monoallelic CDK12 mutations was highest in bladder cancer (3.7%); followed by prostate (3.4%), esophago-gastric (2.1%) and uterine cancers (2.1%). Biallelic CDK12 inactivation was highest in prostate cancer (1.8%), followed by ovarian (1.0%) and bladder cancers (0.5%). These results are the first (to our knowledge) to estimate the prevalence of monoallelic and biallelic CDK12 mutations across multiple cancer types encompassing over 15,000 cases
%K prostate cancer
%K CDK12
%K genetics
%K immunotherapy
%K biomarkers
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650168/